Clinical trial · Interventional
High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma
Phase I/II Study of High Dose Irinotecan (Camptosar, CPT-11) in Patients With Recurrent Unresectable Malignant Glioma on Steroids/Anti-epileptics
NCT00283556CI-TRIAL-00003042completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Glioma | Malignant Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Irinotecan (Camptosar, CPT-11) | Drug | Irinotecan | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cohort #1
- description
- Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients. Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.
- interventionNames
- Drug: Irinotecan (Camptosar, CPT-11)
- type
- EXPERIMENTAL
- label
- Cohort #2
- description
- Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients. Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.
- interventionNames
- Drug: Irinotecan (Camptosar, CPT-11)
- type
- EXPERIMENTAL
- label
- Cohort #3
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * recurrent, unresectable primary CNS neoplasm per MRI * ECOG status of 2 or less * no prior therapy with camptothecans * on an enzyme-inducing antiepileptic
References
Publications (0)
Data not yet available
No reference posted for this study.